Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Sues Kyowa Hakko Over Pravachol Patent Infringement

This article was originally published in PharmAsia News

Executive Summary

Israel's Teva Pharmaceutical Industries, the world's largest maker of generic drugs, filed a suit against Kyowa Hakko Kogyo on grounds the Japanese firm violated a patent held by Teva's Hungarian subsidiary. The suit involves a compound for an anti-cholesterol Pravachol (pravastatin sodium), patented in the United States by Bristol Myers Squibb, and for which the Teva subsidiary received a Japanese patent in 2005. Kyowa Hakko said it began producing the raw material in 2003 as the basis for a generic drug it now sells on the domestic Japanese market. The year before, a forerunner of Daiichi Sankyo had owned the Pravachol compound until its patent expired in 2002. (Click here for more - may require a subscription

You may also be interested in...



QUOTED. 24 November 2020. Kees Wesdorp.

Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.

Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue

Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.

US FDA’s Unapproved Drug Initiative Nixed, But Without Agency Buy-In Demise May Be Short-Lived

Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel